JP2013503200A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503200A5
JP2013503200A5 JP2012527065A JP2012527065A JP2013503200A5 JP 2013503200 A5 JP2013503200 A5 JP 2013503200A5 JP 2012527065 A JP2012527065 A JP 2012527065A JP 2012527065 A JP2012527065 A JP 2012527065A JP 2013503200 A5 JP2013503200 A5 JP 2013503200A5
Authority
JP
Japan
Prior art keywords
seq
cancer
antibody
dnl
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012527065A
Other languages
English (en)
Japanese (ja)
Other versions
JP6114936B2 (ja
JP2013503200A (ja
Filing date
Publication date
Priority claimed from US12/644,146 external-priority patent/US7981398B2/en
Priority claimed from US12/731,781 external-priority patent/US8003111B2/en
Priority claimed from US12/752,649 external-priority patent/US8034352B2/en
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed filed Critical
Priority claimed from PCT/US2010/047132 external-priority patent/WO2011026026A1/en
Publication of JP2013503200A publication Critical patent/JP2013503200A/ja
Publication of JP2013503200A5 publication Critical patent/JP2013503200A5/ja
Publication of JP6114936B2 publication Critical patent/JP6114936B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012527065A 2009-08-31 2010-08-30 強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法 Active JP6114936B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US23847309P 2009-08-31 2009-08-31
US61/238,473 2009-08-31
US26630509P 2009-12-03 2009-12-03
US61/266,305 2009-12-03
US12/644,146 2009-12-22
US12/644,146 US7981398B2 (en) 2005-04-06 2009-12-22 PEGylation by the dock and lock (DNL) technique
US31699610P 2010-03-24 2010-03-24
US61/316,996 2010-03-24
US12/731,781 US8003111B2 (en) 2005-04-06 2010-03-25 Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US12/731,781 2010-03-25
US12/752,649 US8034352B2 (en) 2005-04-06 2010-04-01 Tetrameric cytokines with improved biological activity
US12/752,649 2010-04-01
US12/754,140 2010-04-05
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US12/754,740 2010-04-06
US32396010P 2010-04-14 2010-04-14
US61/323,960 2010-04-14
PCT/US2010/047132 WO2011026026A1 (en) 2009-08-31 2010-08-30 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity

Publications (3)

Publication Number Publication Date
JP2013503200A JP2013503200A (ja) 2013-01-31
JP2013503200A5 true JP2013503200A5 (https=) 2016-02-12
JP6114936B2 JP6114936B2 (ja) 2017-04-19

Family

ID=43628420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012527065A Active JP6114936B2 (ja) 2009-08-31 2010-08-30 強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法

Country Status (7)

Country Link
EP (1) EP2473187A4 (https=)
JP (1) JP6114936B2 (https=)
CN (1) CN102596235A (https=)
BR (1) BR112012004274A2 (https=)
CA (1) CA2770351C (https=)
IN (1) IN2012DN01662A (https=)
WO (1) WO2011026026A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102559636B (zh) * 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
GB201412659D0 (en) * 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016037985A1 (en) 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
US10994022B2 (en) * 2015-02-16 2021-05-04 Xintela Ab Detection and treatment of malignant tumours in the CNS
TWI614264B (zh) * 2015-05-20 2018-02-11 免疫功坊股份有限公司 含胜肽核的多臂接合物及其應用
IL263744B2 (en) * 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
CN108061798B (zh) * 2016-11-07 2019-11-08 国药中生生物技术研究院有限公司 检测HBsAg/anti-HBs复合物体系中有效成分的量的方法和应用
CN107217068A (zh) * 2017-07-18 2017-09-29 哈尔滨紫霞生物科技有限公司 一种提高重组犬干扰素‑α融合蛋白抗病毒活性的方法
WO2019222533A1 (en) * 2018-05-18 2019-11-21 Okogen, Inc. Methods of treating ocular melanoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CA2478047C (en) * 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US7544487B2 (en) * 2004-02-13 2009-06-09 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
ES2665422T3 (es) * 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
AU2007343610C1 (en) * 2007-01-17 2013-11-07 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
CA2772572A1 (en) * 2009-08-31 2011-03-03 Ibc Pharmaceuticals, Inc. Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof

Similar Documents

Publication Publication Date Title
JP2013503200A5 (https=)
CN106938051B (zh) 靶向于组织因子的抗体-药物偶联物
JP2020500016A5 (https=)
Jemal et al. Cancer statistics, 2006
JP2017526632A5 (https=)
HRP20211346T1 (hr) Kombinirani pripravci za liječenje raka
WO2020236817A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
CN111050797B (zh) 抗tim-3抗体及其用途
JP2020524174A5 (https=)
JP2018527908A5 (https=)
JP2018529312A5 (https=)
JP2018502051A5 (https=)
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
EP4389226A3 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
JP2017506217A5 (https=)
JP2018516969A5 (https=)
JP2019514844A5 (https=)
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
SI2342234T1 (en) MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL
JP2009539380A5 (https=)
FI3377103T4 (fi) Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
RU2015123032A (ru) Иммунотерапия с применением связывающих агентов
JP2010536378A5 (https=)
JP2013166763A5 (https=)